Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 243 record(s)

Req # A-2019-000919

Adverse Reaction Reports (AERs). Report numbers: E2B_02500807, 000725397, E2B_02501981, E2B_02515296, E2B_02515324.

Organization: Health Canada

231 page(s)
March 2021

Req # A-2019-000990

Adverse Reaction Reports (AERs). Report numbers: E2B_02548160, E2B_02560341, E2B_02563630, E2B_02563720, E2B_02548160; E2B_02560341; E2B_02563630; E2B_02563720.

Organization: Health Canada

45 page(s)
March 2021

Req # A-2019-001001

Adverse Reaction Reports (AERs). Report numbers: 000693191, E2B_02208753, E2B_02501456, E2B_01965732, E2B_02320915 E2B_01977005, E2B_02320916, E2B_01818817, E2B_01821736, 000693898, E2B_01893037, E2B_01893099, E2B_02107256, E2B_01893790.

Organization: Health Canada

115 page(s)
March 2021

Req # A-2019-001319

Adverse Reaction Reports (AERs) for Mezavant and Mesalazine. Report numbers: E2B_02173182, E2B_02173617, E2B_02174032, E2B_02179943, E2B_02153848.

Organization: Health Canada

42 page(s)
March 2021

Req # A-2019-001359

Adverse Drug Reaction (ADR). Report number: E2B_02373859.

Organization: Health Canada

208 page(s)
March 2021

Req # A-2019-001379

Adverse Reaction Reports (AERs). Report numbers: E2B_02636724, E2B_02648583, E2B_02656434.

Organization: Health Canada

38 page(s)
March 2021

Req # A-2019-001625

Adverse Reaction Reports (AERs). Report numbers: E2B_02143421, E2B_02143419, 000728066, E2B_02600712, 000562537, E2B_01659265 E2B_02529343, E2B_02573882.

Organization: Health Canada

134 page(s)
March 2021

Req # A-2019-001709

Adverse Drug Reaction (ADR) for Amphetamine aspartate. Report number: E2B_02675074.

Organization: Health Canada

26 page(s)
March 2021

Req # A-2019-001928

Adverse Reaction Reports (AERs) for GAMMAGARD LIQUID. Report numbers: 000731082, 000731858, 000731863, 000732122.

Organization: Health Canada

8 page(s)
March 2021

Req # A-2019-001930

Adverse Reaction Reports (AERs) for Antihemophilic factor (human). Report numbers: E2B_02857244, E2B_02861318.

Organization: Health Canada

34 page(s)
March 2021
Date modified: